Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-osteopontin antibodies replicate the tumor suppression phenotype in thrombin cleavage-resistant osteopontin knock-in mice.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Proteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.

EMBO molecular medicine·2025
Same author

ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.

PloS one·2025
Same author

Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII-biointerface binding.

Nature materials·2024
Same author

Survivin Promotes Stem Cell Competence for Skin Cancer Initiation.

Cancer discovery·2024
Same author

Antiphospholipid syndrome, monoclonal gammopathy, and cryoglobulinemia overlap leading to recurrent cutaneous microvascular thrombosis: A case report and retrospective cohort study.

EJHaem·2024

Related Experiment Video

Updated: May 20, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.

Michael J Krisinger1, Verena Goebeler, Zhen Lu

  • 1Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada.

Blood
|July 18, 2012
PubMed
Summary

Coagulation and complement pathways interact to regulate injury responses. Thrombin cleaves C5 at a new site, generating intermediates that enhance complement-mediated cell lysis, revealing a new activation paradigm.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: May 20, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

  • Biochemistry
  • Immunology
  • Molecular Biology

Background:

  • Coagulation and complement pathways are crucial for homeostasis and injury response.
  • Dysregulation of these pathways can lead to significant tissue damage.
  • The cooperative mechanisms between coagulation and complement remain incompletely understood.

Purpose of the Study:

  • To investigate the interaction between thrombin (from coagulation) and C5 convertase (from complement) on C5.
  • To identify novel cleavage sites and intermediates generated during C5 activation.
  • To understand how these interactions influence the terminal complement pathway and membrane attack complex formation.

Main Methods:

  • Studied the effects of thrombin and C5 convertase on purified C5 and in plasma.
  • Measured the release of C5a and generation of C5b using biochemical assays.
  • Characterized novel C5 cleavage intermediates and their functional consequences.

Main Results:

  • Thrombin demonstrated poor cleavage at the known R751 site but efficiently cleaved C5 at a novel R947 site.
  • This novel cleavage generated previously undescribed intermediates, C5(T) and C5b(T).
  • Combined thrombin and C5 convertase treatment produced C5b(T), which formed a more lytic C5b(T)-9 complex than the standard C5b-9.

Conclusions:

  • Identified a new paradigm for complement activation involving invariant partnership between thrombin and C5 convertase.
  • Demonstrated that thrombin-generated C5 intermediates significantly enhance terminal complement pathway activity.
  • Findings suggest novel therapeutic targets for diseases involving both coagulation and complement dysregulation.